Emglif M 12.5/500mg Tablet

Emglif M 12.5/500mg Tablet is a combination medication containing two active ingredients: Empagliflozin & Metformin. Empagliflozin belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors, while Metformin is a biguanide antidiabetic medication. This tablet is prescribed to manage type 2 diabetes mellitus by helping to control blood sugar levels through different mechanisms of action.

Uses:

Emglif M 12.5/500mg Tablet is used in the treatment of type 2 diabetes mellitus in adults. Empagliflozin works by inhibiting the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and lowering blood sugar levels. Metformin decreases hepatic glucose production, improves insulin sensitivity, and enhances peripheral glucose uptake, further contributing to glycemic control. Together, these medications help improve glycemic control and may also promote weight loss.

Dosage:

The dosage of Emglif M 12.5/500mg Tablet is determined by the healthcare provider based on factors such as the patient’s medical history, renal function, and response to treatment. It is typically taken orally once daily with a meal to reduce the risk of gastrointestinal side effects associated with Metformin. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed.

Side Effects:

Common side effects associated with Emglif M 12.5/500mg Tablet may include urinary tract infections, genital yeast infections, increased urination, thirst, dizziness, nausea, diarrhea, abdominal discomfort, and headache. These side effects are usually mild and transient. In some cases, more serious side effects such as hypoglycemia (low blood sugar), ketoacidosis, or allergic reactions may occur. Patients should report any adverse reactions to their healthcare provider promptly.

Precautions:

Before using Emglif M 12.5/500mg Tablet, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. This medication may interact with other drugs, so it’s essential to review the patient’s medication regimen to avoid potential interactions. Patients with impaired renal function or a history of ketoacidosis should use Emglif M with caution.

When Not to Use:

Emglif M 12.5/500mg Tablet is contraindicated in patients with a known hypersensitivity to Empagliflozin, Metformin, or any other components of the medication. It should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Patients with severe renal impairment, end-stage renal disease, or a history of lactic acidosis should also avoid this medication.